CJC-1295: GHRH Analog Research Guide

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate natural GH production from the pituitary gland with significantly extended duration of action. CJC-1295 is a modified version of GHRH (1-29) featuring: - 4 amino acid substitutions at key positions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) - 29-30 amino acids depending on DAC addition - Improved resistance to enzymatic breakdown (dipeptidyl peptidase-4) - Half-life: 30-60 minutes - Dosing: Multiple times per day in research protocols - GH Pattern: Pulsatile, mimics natural physiological release - Also Known As: Mod GRF (1-29) - Half-life: 6-8 days (up to 10 days reported) - Dosing: Once weekly in research protocols - Mechanism: DAC component binds to serum albumin, preventing degradation - GH Pattern: Sustained elevation over days - Binds to GHRH receptors on somatotroph cells in the anterior pituitary - Stimulates pulsatile GH release - Increases downstream IGF-1 production in the liver - Mimics natural GHRH with enhanced stability - GH levels: 2-10 fold increase sustained for 6+ days - IGF-1 levels: 1.5-3 fold increase for 9-11 days - Multiple dose protocols maintained IGF-1 elevation for 28+ days In GHRH knockout models, once-daily dosing normalized: - Body weight and length - Body composition - Pituitary RNA and GH mRNA expression (somatotroph cell proliferation) CJC-1295 is commonly studied with: - Ipamorelin: For synergistic GH pulse without cortisol/prolactin increases - BPC-157: For enhanced recovery research - TB-500: For anti-inflammatory and healing studies - Store lyophilized at -20°C for long-term stability - Reconstitute with bacteriostatic water - Refrigerate after reconstitution at 2-8°C Note: This compound is for research purposes only.